We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+41.81%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$368M
AUM Growth
+$22.1M
Cap. Flow
-$24.9M
Cap. Flow %
-6.76%
Top 10 Hldgs %
54.53%
Holding
62
New
16
Increased
11
Reduced
11
Closed
19

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$14M
2
ETNB
89bio
ETNB
+$13.2M
3
SAGE
Sage Therapeutics
SAGE
+$11.4M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.5M
5
CYTK icon
Cytokinetics
CYTK
+$8.36M

Top Sells

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$36.5M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$18.1M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$11.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.43M
5
ASND icon
Ascendis Pharma A/S
ASND
+$8.21M

Sector Composition

Rank Sector Weight
1 Healthcare 73.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
51
DELISTED
Generation Bio
GBIO
– –
-10,000
Closed -$2.1M
MRUS
52
DELISTED
Merus
MRUS
– –
-460,000
Closed -$7.4M
QURE icon
53
uniQure
QURE
$3.22B
– –
-60,000
Closed -$2.7M
VIR icon
54
Vir Biotechnology
VIR
$1.49B
– –
-127,000
Closed -$5.2M
FUSN
55
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-135,000
Closed -$2.36M
EIGR
56
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-9,750
Closed -$2.81M
RETA
57
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-15,300
Closed -$2.39M
BLU
58
DELISTED
BELLUS Health Inc.
BLU
– –
-765,000
Closed -$7.87M
STSA
59
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-35,000
Closed -$1.01M
AKUS
60
DELISTED
Akouos Inc
AKUS
– –
-22,200
Closed -$500K
DRNA
61
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-170,000
Closed -$4.32M
KDMN
62
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,280,000
Closed -$6.55M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Acuta Capital Partners held 62 positions worth $368M, up 6.4% from $346M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Acuta Capital Partners withdrew a net $24.9M in Q3 2020, closing 19 positions and reducing 11 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Compass Pathways worth $13.6M.

  • Acuta Capital Partners's largest Q3 2020 buy was Compass Pathways: 390,000 shares worth $13.6M.
  • Acuta Capital Partners added most to Celldex Therapeutics in Q3 2020, an estimated $6.38M increase.
  • Acuta Capital Partners's biggest Q3 2020 reduction was Iovance Biotherapeutics, cutting an estimated $8.43M.
  • Acuta Capital Partners fully exited Adverum Biotechnologies in Q3 2020, selling an estimated $36.5M.
  • Acuta Capital Partners's ten largest holdings make up 55% of its $368M portfolio in Q3 2020.
  • Acuta Capital Partners opened 16 new positions and closed 19 in Q3 2020.
  • Acuta Capital Partners's portfolio value rose 6.4% quarter-over-quarter to $368M.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.